^
Association details:
| Biomarker: | NRAS mutation |
|---|---|
| Cancer: | Mucosal Melanoma |
| Drug: | cisplatin (DNA synthesis inhibitor) + dacarbazine (DNA synthesis inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Continuous infusion of Endostar combined with chemotherapy in patients with advanced or recurrent mucosal melanoma: A real-world cohort study
Published date:
05/19/2021
Excerpt:
Patients received dacarbazine plus cisplatin or temozolomide plus cisplatin regimens...An objective response was observed in 12 (30.0%) of the 40 evaluable patients, and disease control was achieved in 31 (77.5%) patients....BRAF/KIT/RAS mutation (p = 0.028, HR 0.24, 95% CI: 0.07-0.86) were independently correlated with prolonged OS....Continuous Endostar infusion in combination with chemotherapy was effective and safe for the treatment of advanced or recurrent mucosal melanoma.
Secondary therapy:
recombinant human endostatin
DOI:
10.1200/JCO.2021.39.15_suppl.e21517
